Mesoblast has completed enrollment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease, locking in a key milestone for one of the most closely watched cell therapy programs outside oncology. The 300-patient, sham-controlled study tests a single intradiscal injection with a 12-month primary endpoint focused on pain reduction, with secondary measures including function, quality of life, and opioid discontinuation. Top-line data are expected mid-2027, and the company is targeting a US filing in the third quarter of 2027. The program holds RMAT designation, positioning it for potential priority review if the package meets FDA expectations.
The strategic question is whether a mesenchymal stromal cell therapy can deliver a clinically and payer-meaningful effect in a condition where sham procedures and regression to the mean often blunt treatment-placebo deltas. In back pain, device and interventional categories have learned the hard way that sham response can be substantial. This trial’s design and its choice of a 12-month pain endpoint will be under intense scrutiny for effect size, consistency across sites, and durability beyond one year.
The stakes are unusually high given the addressable population and the opioid backdrop. Discogenic low back pain contributes materially to disability, work loss, and opioid exposure; shifting even a fraction of patients off chronic analgesics with a one-time, procedure-based biologic could resonate with employers and payers if outcomes are durable. For Medical Affairs, the path will demand rigorous education on patient selection—early-stage inflammatory DDD under five years, not end-stage structural collapse—alongside pragmatic evidence on functional recovery and opioid tapering protocols. Expect RWE registries and long-term follow-up to be mandatory complements to any approval to satisfy payers’ need for durability and utilization control.
Commercially, success hinges as much on economics and workflow as on clinical signal. Intradiscal injection is a fluoroscopy-guided procedure performed in interventional pain clinics and ASCs, implying a blended model of drug and procedure reimbursement. Securing appropriate CPT and HCPCS coding, aligning site-of-care economics, and defining prior-authorization criteria will determine speed of uptake. Pricing power will be judged against the cost and outcomes of step-through options such as physical therapy, epidural steroids, radiofrequency ablation, spinal cord stimulation, and ultimately fusion or disc replacement. If the dataset confirms reductions in opioid use and meaningful gains on validated functional scales, that evidence could underpin value-based contracts with employer plans and integrated delivery networks.
For the broader industry, the Mesoblast program is a bellwether for the next chapter of regenerative medicine—moving from rare, high-cost settings into prevalent musculoskeletal disease. RMAT status signals regulatory openness, but the bar for CMC robustness, comparability, and multi-site manufacturing control remains high, particularly for an off-the-shelf cellular product intended for wide distribution. The outcome will inform capital allocation across spine biologics, where multiple players are targeting disc repair with cell-based and protein therapeutics, and could catalyze cross-border dealmaking at the interface of medtech, interventional pain, and specialty pharma.
What to watch next: the magnitude of pain reduction versus sham at 12 months, concordant improvements in function, statistically credible opioid discontinuation rates, and clean safety around radiculopathy and infection. If those pieces align, the remaining question is whether a first-in-category, procedure-delivered cell therapy can translate a positive readout into rapid, payer-backed standard-of-care change—or whether the market will demand head-to-heads and expansive real-world evidence before shifting longstanding treatment algorithms.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
